Select a medication above to begin.
YF-Vax
yellow fever vaccine, live
Adult Dosing .
Dosage forms: INJ
yellow fever prevention
- [0.5 mL SC x1]
- Start: >10 days prior to yellow fever exposure; Info: for high risk patients including travel or residence in yellow fever endemic area and yellow fever lab workers; repeat dose x1 prior to next travel with exposure risk if pregnant at time of 1st dose or if stem cell transplant after last dose; repeat dose q10y if HIV-positive with exposure risk, lab worker with low antibody titer, or higher risk travel; International Certificate of Vacc. to enter some countries, see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ
yellow fever prevention
- [9 mo and older]
- Dose: 0.5 mL SC x1; Start: >10 days prior to yellow fever exposure; Info: for high risk patients including travel or residence in yellow fever endemic area; may administer to patients 6-8 mo, contact state health department or CDC; repeat dose x1 prior to next travel with exposure risk if pregnant at time of 1st dose or if stem cell transplant after last dose; repeat dose q10y if HIV-positive with exposure risk or higher risk travel; International Certificate of Vacc. to enter some countries, see CDC Pre-Travel Vaccine recommendations in Guidelines > Specialties > Infectious Diseases
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- patients <6 mo
- hypersensitivity to drug or ingredient
- hypersensitivity to gelatin
- hypersensitivity to egg or egg product
- hypersensitivity to chicken protein
- breastfeeding of infants <9 mo
- immunocompromised patients
- HIV infection, symptomatic
- HIV infection with CD4 <200
- HIV infection with CD4 <15% (patients <6 yo)
- thymic disease
- thymic disease history
- XRT, concurrent
- caution: patients of childbearing potential
- caution: patients 6-8 mo
- caution: patients >60 yo
- caution: illness, acute moderate-severe
- caution: asymptomatic HIV infection with CD4 200-500
Drug Interactions .
Overview
yellow fever vaccine, live
live vaccine
- live vaccine
Contraindicated
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- amivantamab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- asciminib
- atezolizumab
- atidarsagene autotemcel
- avelumab
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- belantamab mafodotin
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brensocatib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- busulfan
- cabazitaxel
- canakinumab
- capecitabine
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- cladribine oral
- clofarabine
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dostarlimab
- doxorubicin
- dupilumab
- durvalumab
- duvelisib
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- erdafitinib
- eribulin
- etanercept
- etoposide
- etrasimod
- etuvetidigene autotemcel
- everolimus
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
- futibatinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- icotrokinra
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- ipilimumab
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lazertinib
- lebrikizumab
- leflunomide
- lenalidomide
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methylprednisolone
- mirikizumab
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- nelarabine
- nemolizumab
- nipocalimab
- nivolumab
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- palbociclib
- peginterferon alfa 2a
- pembrolizumab
- pemetrexed
- penpulimab
- pentostatin
- pertuzumab
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- prednisolone
- prednisone
- procarbazine
- regorafenib
- relacorilant
- retifanlimab
- revumenib
- rilonacept
- rilzabrutinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- rucaparib
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- selumetinib
- sevabertinib
- sibeprenlimab
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sirolimus topical
- sorafenib
- spesolimab
- sunitinib
- tacrolimus
- tafasitamab
- taletrectinib
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- trabectedin
- tralokinumab
- trastuzumab
- tremelimumab
- triamcinolone
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- ziftomenib
Avoid/Use Alternative
- ado-trastuzumab emtansine
- avutometinib
- belzutifan
- bevacizumab
- capmatinib
- cetuximab
- defactinib
- dordaviprone
- fam-trastuzumab deruxtecan
- interferon gamma 1b
- lurbinectedin
- margetuximab
- methotrexate
- mitomycin
- nilotinib
- obecabtagene autoleucel
- olaparib
- panitumumab
- remibrutinib
- ripretinib
- sunvozertinib
- telisotuzumab vedotin
- tezepelumab
- vandetanib
- zanidatamab
- zenocutuzumab
- zongertinib
Monitor/Modify Tx
- budesonide rectal
- chikungunya vaccine, live
- dengue vaccine, live
- ebola vaccine, live
- glatiramer
- influenza nasal vaccine, live
- interferon beta 1a
- interferon beta 1b
- measles/mumps/rubella vaccine, live
- peginterferon beta 1a
- smallpox vaccine, live
- smallpox/mpox vaccine, live
- tuberculin purified protein derivative
- varicella vaccine, live
Caution Advised
- leniolisib
Adverse Reactions .
Serious Reactions
- anaphylaxis
- viscerotropic disease, vaccine-associated
- neurotropic disease, vaccine-associated
- Guillain-Barre syndrome
- seizures
- neurologic disorders
- asthma
Common Reactions
- injection site reaction
- headache
- fever
- myalgia
- malaise
- asthenia
- rash
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; if given during pregnancy, check antibody titers due to immunologic failure risk; risk of virus transmission low based on limited human data
Individuals of Reproductive Potential
avoid pregnancy by using effective contraception x4wk after vaccination in patients of childbearing potential
Lactation
Clinical Summary
avoid use while breastfeeding infants <9 mo unless travel to endemic area cannot be avoided or postponed; possible risk of infantile seizures and encephalitis based on limited human data; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for yellow fever vaccine: unknown; CYP450: unknown
Excretion: for yellow fever vaccine: unknown; Half-life: unknown
Subclass: Travel Vaccines
Mechanism of Action
for yellow fever vaccine: exact mechanism of action unknown; induces antibody formation
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.